Champions Oncology, Inc.

NASDAQ:CSBR

Biotechnology

Healthcare
$4.44 -1.17%

-$0.08 today

Market cap
$61.80M
Beta
0.40
P/E (TTM)
-41.0
EPS (TTM)
-$0.16
52W Low $5.50High $9.63

Volume 0.01M

Average 0.01M

CSBR Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Champions Oncology, Inc.NASDAQ: CSBR

Net Receivables · Q3 FY2026 · quarter ended Jan 2026

Net receivables falls 23.5% from a year ago

Net receivables stood at $12.07M at the end of Q3 FY2026, down 23.5% from a year earlier and up 4.6% from the prior quarter. Over 3 fiscal years it compounded at +5.7% a year.

Context

  • Net receivables amounted to 42.4% of total assets at the end of Q3 FY2026, down 9.1 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -23.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJan 2026
$12.07M+4.6% QoQ
Last fiscal yearApr 2025
$11.23M+17.9% YoY
Year agoJan 2025
$15.78M-23.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-23.5%——
1 year+17.9%——
3-year CAGR+5.7%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
11.23M USD
Year-over-year change
+17.9%
4-year CAGR
+12.6%

Net Receivables vs competitors

How CSBR compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -23.5% is the 3rd highest of 6, against a peer median of -42.0%.
  • Net receivables amounts to 42.4% of total assets for CSBR, versus a peer median of 0.0%.
CSBR Competitors
Net Receivables for CSBR and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
STROSutro Biopharma, Inc.Mar 2026$12.48M USD-7.9%-17.7%5.2%
CSBRChampions Oncology, Inc.Jan 2026$12.07M USD-23.5%+5.7%42.4%
IFRXInflaRx N.V.Mar 2026€1.65M EUR-2.4%-0.1%3.4%
ARTVArtiva Biotherapeutics, Inc.Mar 2026$600K USD-42.0%+13.5%0.6%
CNTBConnect Biopharma Holdings LimitedDec 2025$161K USD-84.7%-11.5%0.3%
STTKShattuck Labs, Inc.Mar 2026$0 USD——0.0%
ORMPOramed Pharmaceuticals Inc.Mar 2026$0 USD——0.0%
ATRAAtara Biotherapeutics, Inc.Mar 2026$0 USD-100.0%-68.5%0.0%
IMAImageneBio IncMar 2026$0 USD——0.0%
KLRSKalaris Therapeutics IncMar 2026$0 USD——0.0%
Peer median (excluding CSBR) —-42.0%-11.5%0.0%

Competitors are the stored peer set for CSBR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Apr 2021
FY2022
Apr 2022
FY2023
Apr 2023
FY2024
Apr 2024
FY2025
Apr 2025
Cash & Equivalents4.69M9.01M10.12M2.62M9.79M
Short-term Investments00000
Net Receivables6.99M9.51M8.01M9.53M11.23M
Inventory00000
Other Current Assets001.33M1.5M1.35M
Total Current Assets12.63M19.66M19.46M13.64M22.37M
Property, Plant & Equipment (Net)14.61M15.36M14.5M11.97M9.46M
Goodwill335K335K335K335K335K
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets15K15K15K185K185K
Total Non-current Assets14.96M15.71M14.85M12.49M9.98M
Total Assets27.59M35.38M34.31M26.13M32.34M
Account Payables1.89M2.87M5.33M5.8M4.25M
Short-term Debt00000
Tax Payables00000
Deferred Revenue6.26M11.07M12.78M12.09M15.44M
Other Current Liabilities072K145K150K135K
Total Current Liabilities11.2M17.48M21.73M21.54M23.85M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities181K391K551K401K85K
Total Non-current Liabilities8.96M8.8M7.94M6.49M4.72M
Total Liabilities20.16M26.28M29.68M28.04M28.57M
Common Stock13K14K14K14K14K
Retained Earnings(72.53M)(71.98M)(77.32M)(84.59M)(79.89M)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity7.43M9.1M4.64M(1.9M)3.77M
Total Debt9.6M9.47M8.6M7.43M6.11M
Net Debt4.91M459K(1.52M)4.81M(3.68M)

Champions Oncology, Inc.

NASDAQ:CSBR

Intrinsic Alpha fair value

Locked

Current Price

$4.44

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.